Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
06 Dec 2021
// ENDPTS
https://endpts.com/recordati-acquires-eusa-pharma-and-its-4-rare-disease-drugs-but-analysts-question-strategy-behind-the-deal/
02 Dec 2021
// BUSINESSWIRE
02 Dec 2021
// PRESS RELEASE
https://ir.beigene.com/news-details/?id=f0f5a767-78bb-4998-9593-5f9ea685026e
17 Aug 2021
// BUSINESSWIRE
25 Jan 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210125005360/en/EUSA-Pharma-and-BeiGene-Announce-Acceptance-of-a-Biologics-License-Application-for-SYLVANT%C2%AE-Siltuximab-for-Injection-in-China
Details:
Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small molecule.
Lead Product(s): Dinutuximab
Therapeutic Area: Oncology Brand Name: Qarziba
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Recordati
Deal Size: $847.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 03, 2021
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Recordati
Deal Size : $847.0 million
Deal Type : Acquisition
Details : Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small ...
Brand Name : Qarziba
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 03, 2021
Details:
This pivotal study will evaluate the efficacy and safety of standard of care (SOC) with or without intravenous siltuximab in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection.
Lead Product(s): Siltuximab
Therapeutic Area: Infections and Infectious Diseases Brand Name: Sylvant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Lead Product(s) : Siltuximab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This pivotal study will evaluate the efficacy and safety of standard of care (SOC) with or without intravenous siltuximab in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection.
Brand Name : Sylvant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 17, 2020
Details:
QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.
Lead Product(s): Dinutuximab
Therapeutic Area: Oncology Brand Name: Qarziba
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : BeiGene
Deal Size : Not Applicable
Deal Type : Not Applicable
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA® (Dinu...
Details : QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.
Brand Name : Qarziba
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 09, 2020
Details:
The Phase 2 portion of the study was designed to assess the safety, tolerability, and anti-tumor activity of the full dose and schedule of PO tivozanib, in combination with IV nivolumab.
Lead Product(s): Tivozanib,Nivolumab
Therapeutic Area: Oncology Brand Name: Fotivda
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Aveo Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Lead Product(s) : Tivozanib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Aveo Oncology
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 2 portion of the study was designed to assess the safety, tolerability, and anti-tumor activity of the full dose and schedule of PO tivozanib, in combination with IV nivolumab.
Brand Name : Fotivda
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 05, 2020
Details:
Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling.
Lead Product(s): Siltuximab
Therapeutic Area: Infections and Infectious Diseases Brand Name: Sylvant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2020
Lead Product(s) : Siltuximab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induc...
Brand Name : Sylvant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 02, 2020
Details:
A third of patients with COVID-19 taking EUSA Pharma's interleukin (IL)-6 targeted monoclonal antibody siltuximab have experienced a clinical improvement, reveals a case-control trial in Italy.
Lead Product(s): Siltuximab
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Lead Product(s) : Siltuximab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A third of patients with COVID-19 taking EUSA Pharma's interleukin (IL)-6 targeted monoclonal antibody siltuximab have experienced a clinical improvement, reveals a case-control trial in Italy.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 01, 2020
Details:
The step was followed by the release of initial data from China suggesting a role of IL-6 in the development of Acute Respiratory Distress Syndrome as a result of COVID-19.
Lead Product(s): Siltuximab
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Lead Product(s) : Siltuximab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The step was followed by the release of initial data from China suggesting a role of IL-6 in the development of Acute Respiratory Distress Syndrome as a result of COVID-19.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 18, 2020
ABOUT THIS PAGE
Eusa Pharma is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Dinutuximab bulk with DMF offered by Eusa Pharma
LOOKING FOR A SUPPLIER?